Mereo BioPharma Group plc
MREO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 74.3% | – | 50.9% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -260.6% | – | 51.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -294.7% | – | 34.9% |
| EPS Diluted | -0.29 | -1,100.22 | -1,750.35 | 749.65 |
| % Growth | 100% | 37.1% | -333.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |